J. Davis, L. Furstenthal, A. Desai, T. Norris, S. Sutaria et al., The microeconomics of personalized medicine: today's challenge and tomorrow's promise, Nature Reviews Drug Discovery, vol.295, issue.4, pp.279-286, 2009.
DOI : 10.1038/nrd2825

K. Phillips, D. Veenstra, S. Ramsey, V. Bebber, S. Sakowski et al., Genetic testing and pharmacogenomics: issues for determining the impact to healthcare delivery and costs, Am J Manag Care, vol.10, issue.7, pp.425-432, 2004.

D. Houtsma, H. Guchelaar, and H. Gelderblom, Pharmacogenetics in Oncology: A Promising Field, Current Pharmaceutical Design, vol.16, issue.2, pp.155-163, 2010.
DOI : 10.2174/138161210790112719

S. Vegter, C. Boersma, M. Rozenbaum, B. Wilffert, G. Navis et al., Pharmacoeconomic Evaluations of Pharmacogenetic and Genomic Screening Programmes, PharmacoEconomics, vol.44, issue.12, pp.569-587, 2008.
DOI : 10.2165/00019053-200826070-00005

P. Deverka, Pharmacogenomics, Evidence, and the Role of Payers, Public Health Genomics, vol.12, issue.3, pp.149-157, 2009.
DOI : 10.1159/000189627

M. Drummond, O. Brien, B. Stoddart, and G. , Methods for the economic evaluation of health care programs. Second Edition, 1997.

. Evans-bjt, L. Veer, H. Dai, M. Van-de-vijver, Y. He et al., Distinguishing Product and Practice Regulation in Personalized Medicine, Clinical Pharmacology & Therapeutics, vol.3, issue.2, pp.288-293530, 2002.
DOI : 10.1038/sj.clpt.6100042

M. Van-de-vijver, Y. He, . Van-'t, L. Veer, H. Dai et al., A Gene-Expression Signature as a Predictor of Survival in Breast Cancer, New England Journal of Medicine, vol.347, issue.25, pp.1999-2009, 2002.
DOI : 10.1056/NEJMoa021967

F. Bertucci, P. Finetti, N. Cervera, D. Maraninchi, P. Viens et al., Gene Expression Profiling and Clinical Outcome in Breast Cancer, OMICS: A Journal of Integrative Biology, vol.10, issue.4, pp.429-443, 2006.
DOI : 10.1089/omi.2006.10.429

F. Bray, R. Sankila, J. Ferlay, and D. Parkin, Estimates of cancer incidence and mortality in Europe in 1995, European Journal of Cancer, vol.38, issue.1, pp.99-166, 2002.
DOI : 10.1016/S0959-8049(01)00350-1

M. Piccart, D. De-valeriola, D. Lago, L. De-azambuja, E. Demonty et al., Adjuvant chemotherapy in 2005: Standards and beyond, The Breast, vol.14, issue.6, pp.439-445, 2005.
DOI : 10.1016/j.breast.2005.08.004

E. Mamounas, J. Bryant, B. Lembersky, L. Fehrenbacher, S. Sedlacek et al., Paclitaxel After Doxorubicin Plus Cyclophosphamide As Adjuvant Chemotherapy for Node-Positive Breast Cancer: Results From NSABP B-28, Journal of Clinical Oncology, vol.23, issue.16, pp.3686-3696, 2005.
DOI : 10.1200/JCO.2005.10.517

M. Martin, T. Pienkowski, J. Mackey, M. Pawlicki, J. Guastalla et al., Adjuvant Docetaxel for Node-Positive Breast Cancer, New England Journal of Medicine, vol.352, issue.22, pp.2302-2313, 2005.
DOI : 10.1056/NEJMoa043681

H. Roche, P. Fumoleau, M. Spielmann, J. Canon, T. Delozier et al., Sequential Adjuvant Epirubicin-Based and Docetaxel Chemotherapy for Node-Positive Breast Cancer Patients: The FNCLCC PACS 01 Trial, Journal of Clinical Oncology, vol.24, issue.36, pp.5664-5671, 2006.
DOI : 10.1200/JCO.2006.07.3916

A. Buzdar, S. Singletary, V. Valero, D. Booser, N. Ibrahim et al., Evaluation of paclitaxel in adjuvant chemotherapy for patients with operable breast cancer: preliminary data of a prospective randomized trial, Clin Cancer Res, vol.8, issue.5, pp.1073-1079, 2002.

F. Cognetti and D. Giannarelli, Benefit of taxanes as adjuvant chemotherapy for early breast cancer: pooled analysis of 15,500 patients, Cancer, vol.106, issue.11, pp.2337-2344, 2006.

M. Campone, P. Fumoleau, E. Bourbouloux, P. Kerbrat, and H. Roche, Taxanes in adjuvant breast cancer setting: Which standard in Europe?, Critical Reviews in Oncology/Hematology, vol.55, issue.3, pp.167-175, 2005.
DOI : 10.1016/j.critrevonc.2005.04.003

D. Veenstra, M. Higashi, and K. Phillips, Assessing the cost-effectiveness of pharmacogenomics, AAPS PharmSci, vol.2, issue.3, p.29, 2000.
DOI : 10.1208/ps020329

C. Flowers and D. Veenstra, The Role of Cost-Effectiveness Analysis in the Era of Pharmacogenomics, PharmacoEconomics, vol.57, issue.9, pp.481-493, 2004.
DOI : 10.2165/00019053-200422080-00001

A. Guttmacher and F. Collins, Genomic Medicine ??? A Primer, New England Journal of Medicine, vol.347, issue.19, pp.1512-1520, 2002.
DOI : 10.1056/NEJMra012240

F. Bertucci, V. Nasser, S. Granjeaud, F. Eisinger, A. J. Tagett et al., Gene expression profiles of poor-prognosis primary breast cancer correlate with survival, Human Molecular Genetics, vol.11, issue.8, pp.863-872, 2002.
DOI : 10.1093/hmg/11.8.863

F. Bertucci, N. Borie, H. Roché, T. Bachelot, L. Doussal et al., Gene expression profile predicts outcome after anthracyclinebased adjuvant chemotherapy in early breast cancer, Breast Cancer Res Treat, 2010.
URL : https://hal.archives-ouvertes.fr/hal-00594464

P. Marino, C. Siani, H. Roche, C. Protiere, P. Fumoleau et al., Cost-effectiveness of adjuvant docetaxel for nodepositive breast cancer patients: results of the PACS 01 economic study, Ann Oncol, 2010.

S. Finkler, The Distinction Between Cost and Charges, Annals of Internal Medicine, vol.96, issue.1, pp.102-109, 1982.
DOI : 10.7326/0003-4819-96-1-102

A. Sims, K. Ong, R. Clarke, and A. Howell, High-throughput genomic technology in research and clinical management of breast cancer. Exploiting the potential of gene expression profiling: is it ready for the clinic?, Breast Cancer Research, vol.4, issue.5, p.214, 2006.
DOI : 10.1186/bcr433

D. Roden, R. Altman, N. Benowitz, D. Flockhart, K. Giacomini et al., Pharmacogenomics: Challenges and Opportunities, Annals of Internal Medicine, vol.145, issue.10, pp.749-757, 2006.
DOI : 10.7326/0003-4819-145-10-200611210-00007

J. Swen, T. Huizinga, H. Gelderblom, E. De-vries, W. Assendelft et al., Translating Pharmacogenomics: Challenges on the Road to the Clinic, PLoS Medicine, vol.12, issue.8, p.209, 2007.
DOI : 10.1371/journal.pmed.0040209.t004

J. Ross, C. Hatzis, W. Symmans, L. Pusztai, and G. Hortobagyi, Commercialized Multigene Predictors of Clinical Outcome for Breast Cancer, The Oncologist, vol.13, issue.5, pp.477-493, 2008.
DOI : 10.1634/theoncologist.2007-0248

G. Lyman and N. Kuderer, Gene Expression Profile Assays as Predictors of Recurrence-Free Survival in Early-Stage Breast Cancer: A Metaanalysis, Clinical Breast Cancer, vol.7, issue.5, pp.372-379, 2006.
DOI : 10.3816/CBC.2006.n.053

J. Hornberger, L. Cosler, and G. Lyman, Economic analysis of targeting chemotherapy using a 21-gene RT-PCR assay in lymph-node-negative, estrogenreceptor-positive , early-stage breast cancer, Am J Manag Care, vol.11, issue.5, pp.313-324, 2005.

G. Lyman, L. Cosler, N. Kuderer, and J. Hornberger, Impact of a 21-gene RT-PCR assay on treatment decisions in early-stage breast cancer, Cancer, vol.7, issue.6, pp.1011-1018, 2007.
DOI : 10.1002/cncr.22506

N. Oestreicher, S. Ramsey, H. Linden, J. Mccune, . Van-'t et al., Gene expression profiling and breast cancer care: What are the potential benefits and policy implications?, Genetics in Medicine, vol.18, issue.6, pp.380-389, 2005.
DOI : 10.1097/01.GIM.0000170776.31248.75

M. Chen and B. Nalebuff, One-Way Essential Complements, SSRN Electronic Journal, vol.1588, 2006.
DOI : 10.2139/ssrn.937384

J. Gabszewicz, N. Sonnac, and X. Wauthy, On price competition with complementary goods, Economics Letters, vol.70, issue.3, pp.431-437, 2001.
DOI : 10.1016/S0165-1765(00)00383-9

R. Hirth, M. Chernew, E. Miller, A. Fendrick, and W. Weissert, Willingness to Pay for a Quality-adjusted Life Year, Medical Decision Making, vol.336, issue.3, pp.332-342, 2000.
DOI : 10.1177/0272989X0002000310

J. Pinto-prades, G. Loomes, and R. Brey, Trying to estimate a monetary value for the QALY, Journal of Health Economics, vol.28, issue.3, pp.553-562, 2009.
DOI : 10.1016/j.jhealeco.2009.02.003

H. Mason, M. Jones-lee, and C. Donaldson, Modelling the monetary value of a QALY: a new approach based on UK data, Health Economics, vol.375, issue.1, pp.933-950, 2009.
DOI : 10.1002/hec.1416